The Technical Analyst
Brain Scientific Inc. [BRSF]
Exchange: PNK Industry: Medical Devices
Brain Scientific Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.750
America/New_York / 8 aug 2023 @ 09:45
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.932 mill |
| EPS: | -12.99 |
| P/E: | -0.0600 |
| Earnings Date: | May 03, 2024 |
| SharesOutstanding: | 1.243 mill |
| Avg Daily Volume: | 0 mill |
| RATING 2023-09-05 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | n/a | n/a | ||||
| Ebit | n/a | n/a | ||||
| Asset | n/a | n/a | ||||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0600 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.0600 | industry: PE -6.92 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.682 - 0.818 ( +/- 9.07%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-02-03 | Cloutier Daniel Danny | Buy | 362 069 | Options to Purchase Common Stock |
| 2022-08-19 | Cloutier Daniel Danny | Buy | 304 608 | Options to purchase Common Stock |
| 2021-11-08 | Cloutier Daniel Danny | Buy | 0 | |
| 2022-08-19 | Olivier Thomas | Buy | 304 608 | Options to purchase Common Stock |
| 2022-08-19 | Mackenzie Donald S | Buy | 304 608 | Options to purchase Common Stock |
| INSIDER POWER |
|---|
| 89.29 |
| Last 29 transactions |
| Buy: 44 442 292 | Sell: 6 415 437 |
Forecast:
01:40 - $0.522
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.750 (0.00% ) |
| Volume | 0.0000 mill |
| Avg. Vol. | 0 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BRSF
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BRSF
Brain Scientific Inc., a medtech company, provides neurology-focused medical devices and electric motors in the United States. The company also develops motor platforms; an ultra-precise micro dosing pump; and motion products. The company offers NeuroCap, a disposable and soft layered cap with an integrated electrode circuit that is designed to address existing problems of conventional EEG systems; and NeuroEEG, a clinical-grade device for prescription use to acquire, record, transmit, and display electrical brain activity for patients of all ages, as well as NeuroNet Cloud, a database where brain data can be stored and analyzed. Brain Scientific Inc. was founded in 2013 and is headquartered in Sarasota, Florida.
Latest Press Releases
2021-10-04 08:00:00 - Press Release
Brain Scientific And Piezo Motion Complete Merger And Announce Hassan Kotob As Ceo Of The Combined Company
The company also announced the closing of a $5 million financing round from u.s. institutions. both parties to combine their proprietary technology and introduce innovative products. the company also announced the closing of a $5 million financing round from u.s. institutions. both parties to combine their proprietary technology and introduce innovative products.
2021-06-16 08:30:00 - Press Release
Brain Scientific Enters Into Merger Agreement With Piezo Motion
Closing contemplates minimum $5 million capital investment for combined company closing contemplates minimum $5 million capital investment for combined company
2021-03-12 08:30:00 - Press Release
Brain Scientific Featured In Syndicated Broadcast Covering Receipt Of Fda Clearance For Next-gen Neurocap Eeg Headset
New york, march 12, 2021 (globe newswire) -- via investorwire -- brain scientific inc. (otcqb: brsf ) today announces it has been featured in a broadcast via networknewsaudio (nna), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. the audio press release covers brain scientific's receipt of u.s. food and drug administration (“fda”) 510(k) clearance for its next-generation neurocap™ device. neurocap™ is an advanced electroencephalogram (eeg) electrode array used to obtain rapid eegs in routine clinical and research settings where recording of stat eegs is desired.
2021-03-09 08:30:00 - Press Release
Brain Scientific Announces Fda Clearance For Next-gen Neurocap™ Eeg Headset
New york, march 09, 2021 (globe newswire) -- via investorwire -- brain scientific inc. (otcqb: brsf), a neurology-focused medical device and software company, announced today it received u.s. food and drug administration (fda) 510(k) clearance for its next generation neurocap™ device. neurocap™ is an advanced electroencephalogram (eeg) electrode array used to obtain rapid eegs in routine clinical and research settings where recording of stat eegs is desired.
Latest News
2022-09-28 10:47:05 - Proactive Investors
Tiziana Life Sciences presents intranasal foralumab at Preserving the Brain scientific conference in Italy
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has presented posters on intranasal foralumab at the Preserving the Brain scientific conference, a scientific forum and exhibit on neurodegenerative diseases as part of human brains held at the Fondazione Prada in Milan, Italy. Further, the company said the first secondary progressive multiple sclerosis patient receiving intranasal foralumab was interviewed by Tiziana scientific advisory board chairman Howard Weiner.
2021-10-04 08:00:00 - GlobeNewsWire
Brain Scientific and Piezo Motion Complete Merger and Announce Hassan Kotob as CEO of the Combined Company
The company also announced the closing of a $5 million financing round from U.S. institutions. Both parties to combine their proprietary technology and introduce innovative products. The company also announced the closing of a $5 million financing round from U.S. institutions. Both parties to combine their proprietary technology and introduce innovative products.
2021-06-16 08:30:00 - GlobeNewsWire
Brain Scientific Enters into Merger Agreement with Piezo Motion
Closing Contemplates Minimum $5 Million Capital Investment For Combined Company Closing Contemplates Minimum $5 Million Capital Investment For Combined Company
2021-03-12 08:30:00 - GlobeNewsWire
Brain Scientific Featured in Syndicated Broadcast Covering Receipt of FDA Clearance for Next-Gen NeuroCap EEG Headset
NEW YORK, March 12, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Brain Scientific Inc. (OTCQB: BRSF ) today announces it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers Brain Scientific's receipt of U.S. Food and Drug Administration (“FDA”) 510(k) clearance for its next-generation NeuroCap™ device. NeuroCap™ is an advanced Electroencephalogram (EEG) electrode array used to obtain rapid EEGs in routine clinical and research settings where recording of STAT EEGs is desired.
2021-03-09 08:30:00 - GlobeNewsWire
Brain Scientific Announces FDA Clearance for Next-Gen NeuroCap™ EEG Headset
NEW YORK, March 09, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Brain Scientific Inc. (OTCQB: BRSF), a neurology-focused medical device and software company, announced today it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its next generation NeuroCap™ device. NeuroCap™ is an advanced Electroencephalogram (EEG) electrode array used to obtain rapid EEGs in routine clinical and research settings where recording of STAT EEGs is desired.